Oncology Data Advisor® · Pain Awareness Month With NIda Khan, MD, and Joseph Kalis, PharmD, BCOP This interview features Oncology Data Advisor Fellows Forum member Dr. Nida Khan, a Medical Oncology and Palliative Care Fellow at The Ohio State University, and Editorial Board member Dr. Joseph Kalis, Ambulatory Oncology Pharmacy Specialist at the University of Colorado Health, in a multidisciplinary conversation for Pain Awareness Month. Dr. Khan and Dr. Kalis explain the different types of pain trajectories, particularly for patients with cancer, and the unique ways in which they approach pain management in their different specialties.
Raising Awareness of Prostate Cancer in Transgender Women With Farnoosh Nik-Ahd, MD, and Stephen Freedland, MD
Oncology Data Advisor® · Raising Awareness of Prostate Cancer in Transgender Women: Farnoosh Nik-Ahd and Stephen Freedland This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, and Dr. Farnoosh Nik-Ahd, Urology Resident at the University of California, San Francisco (UCSF), discussing the risks and incidence of prostate cancer in transgender women. Dr. Nik-Ahd shares the inspiration for her recent first-author study, Prostate Cancer Is Not Just a Man's Concern, the results that she and her team found, and their implications for prostate cancer screening and diagnosis standards for transgender women.
Understanding the Tumor Microenvironment to Unlock the Key to Oncology Drug Development With Jesus Garcia, PhD
Oncology Data Advisor® · Understanding the Tumor Microenvironment for Oncology Drug Development With Jesus Garcia, PhD This interview features Jesus Garcia, PhD, a tissue and liquid biopsy expert who analyzes trial sponsors' clinical protocols and aids them in developing relevant biomarker strategies for their trials. Dr. Garcia discusses his passion for understanding the tumor microenvironment, its implications in drug development, and breakthrough strategies in pathology and technology that are leading to expanded therapeutic options for patients.
Oncology Data Advisor® · Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with non-Hodgkin lymphomas. Recently, results were presented at the European Hematology Association (EHA) Congress for Cohorts 2A and 2B of the phase 1/2 EPCORE NHL-2 trial, which is investigating an epcoritamab combination for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Center and one of the study's investigators, discusses the significance of these results and the efficacy of epcoritamab across the various tumor types being studied.
Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma with Kohei Shitara, MD
Oncology Data Advisor® · Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma: Kohei Shitara, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Kohei Shitara, a Medical Oncologist at the National Cancer Center Hospital East in Japan, discusses his two abstracts investigating the efficacy of zolbetuximab in gastric cancers.
Studying Accelerated Brain Age and Neurocognitive Impairments in Childhood Cancer Survivors With Nicholas Phillips, MD, PhD
Oncology Data Advisor® · Accelerated Brain Age in Survivors of Childhood Cancer With Nicholas Phillips, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Nicholas Phillips, a Physician Scientist at St. Jude Children's Research Hospital, discusses his research investigating accelerated brain age and associated neurocognitive impairments experienced by childhood cancer survivors.
Oncology Data Advisor® · Reducing Drug Waste Through Dose Rounding of Bevacizumab With Puneeth Indurlal, MD In this interview from the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, Dr. Puneeth Indurlal, Senior Director for Care Transformation at the US Oncology Network, discusses his team's abstract regarding dose rounding of bevacizumab, the potential for minimizing drug waste, and reducing the cost of care.
Impacts of Social Determinants of Health on Triple-Negative Breast Cancer Treatment With Nicholas Robert, MD
Oncology Data Advisor® · Impact of Social Determinants of Health on TNBC Treatment With Nicholas Robert, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor speaks with Dr. Nicholas Robert, Chief Medical Officer for Ontada, about his team's abstract regarding the impacts of social determinants of health on genetic testing and treatment selection in triple-negative breast cancer (TNBC).
Oncology Data Advisor® · Supporting Patients Through Employment Disruptions During Cancer With Michael Halpern, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Michael Halpern, Medical Officer in the National Cancer Institute's Healthcare Delivery Research Program, discusses his team's study investigating the effects of employment disruptions on financial hardship experienced by patients with cancer. Dr. Halpern shares advice for how employers can provide support and accommodation in the workplace for their employees during cancer treatment, as well as advice for clinicians on how to partner with patients to address financial hardships.
Hematology/Oncology Trainee Experiences During the COVID-19 Pandemic and Beyond With Samuel Kareff, MD, MPH, and Ana Velazquez Mañana, MD
Oncology Data Advisor® · Hematology/Oncology Trainee Experiences During COVID-19: Samuel Kareff and Ana Velazquez Mañana This Oncology Data Advisor® Fellows Forum Interview features Dr. Samuel Kareff, Hematology/Oncology Chief Fellow at the University of Miami Sylvester Comprehensive Cancer Center, in discussion with Dr. Ana Velazquez Mañana, an Assistant Professor of Medicine in the Division of Hematology-Oncology at the University of California, San Francisco (UCSF), regarding the unique challenges faced by hematology/oncology trainees during the COVID-19 pandemic. Dr. Velazquez Mañana outlines the impacts on clinical training, research, and career development, as well as the positive changes that have been incorporated into the landscape for hematology/oncology trainees.
Leveraging Community-Academic Partnerships to Improve Care for Latinx AYA Cancer Survivors With Stephanie Smith, MD
Oncology Data Advisor® · Leveraging Community-Academic Partnerships for Latinx AYA Cancer Survivors With Stephanie Smith, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephanie Smith, Pediatric Oncologist at Stanford Medicine, sat down with Oncology Data Advisor to discuss her research on leveraging community-academic partnerships to improve access to survivorship care for Latinx adolescent/young adult (AYA) cancer survivors. Dr. Smith explains the barriers faced by this population and the unique role that community cancer centers play in providing equitable care as patients transition into adult survivorship.
Oncology Data Advisor® · Coping With the Uncertainty of Indolent Non-Hodgkin Lymphoma With Richard Newcomb, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Richard Newcomb, Hematology/Oncology Fellow at Dana-Farber/Mass General Cancer Center, sat down with Oncology Data Advisor to elaborate on his study regarding uncertainty and coping experienced by patients with newly diagnosed indolent non-Hodgkin lymphoma (NHL), as well as strategies for supporting patients facing distress around their diagnosis.
Oncology Data Advisor® · Finding Real-World Response End Points in NSCLC Data Sets With Janet Espirito, PharmD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Janet Espirito, PharmD, a Senior Medical Director at Ontada, sat down with Oncology Data Advisor to discuss her presentation on identifying real-world end points for assessing response in patients receiving novel therapies for metastatic non–small cell lung cancer (NSCLC) outside of clinical trials.
Understanding Sexual Orientation and Gender Identity Data Collection in Oncology With Mandi Pratt-Chapman, PhD
Oncology Data Advisor® · Understanding Sexual Orientation and Gender Identity Data Collection: Mandi Pratt-Chapman, PhD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Mandi Pratt-Chapman, Associate Center Director for Community Outreach, Engagement, and Equity at George Washington University Cancer Center, sat down with Oncology Data Advisor to discuss her abstract on difference-making conditions associated with sexual orientation and gender identity (SOGI) data collection among ASCO members' institutions. Dr. Pratt-Chapman gives additional insight into the importance of SOGI data collection for providing patient-centered care and shares advice for instituting data collection processes in order to help guide clinical decision making for LGBTQIA+ patients.
Trailblazing the Oncology and Palliative Care Fellowship Experience and Finding Your Niche: Richa Thakur, MD, and Nida Khan, MD
Oncology Data Advisor® · The Value of Integrated Palliative Care Training During Fellowship With Richa Thakur, MD In this Oncology Data Advisor® Fellows Forum interview, Richa Thakur, MD, Hematology/Oncology Fellow at Northwell Health, speaks with Nida Khan, MD, a third-year Internal Medicine Resident who is beginning a joint Medical Oncology and Palliative Care Fellowship this July. Dr. Khan discusses the unique opportunities provided by this new type of fellowship, her passions for palliative care and global health, and advice for navigating the fellowship application process to find your niche in the program that is the best fit for you.
Oncology Data Advisor® · Results of the HERIZON-BTC-01 Trial of Zanidatamab in Biliary Tract Cancers With Shubham Pant, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Shubham Pant, Associate Professor in the Department of Medical Oncology at MD Anderson Cancer Center, presented the results of HERIZON-BTC-01, a phase 2b trial investigating zanidatamab in previously treated human epidermal growth factor receptor 2 (HER2)–amplified biliary tract cancers. Afterwards he spoke with Oncology Data Advisor to share more about the efficacy, safety, and future directions for zanidatamab.
Understanding and Improving Quality of Life for Cancer Patients Through Nursing Research With Terri Armstrong, PhD, ANP-BC
Oncology Data Advisor® · Understanding and Improving Quality of Life for Cancer Patients Through Nursing Research Following the recent 48th Oncology Nursing Society (ONS), Terri Armstrong, the Senior Investigator and Deputy Chief of the Neuro-Oncology Branch at the National Institutes of Health (NIH), sat down with Oncology Data Advisor®...
Improving Access to Hereditary Cancer Genetic Testing for Black Individuals and Their Families With Darya Kizub, MD
Oncology Data Advisor® · Developing Telegenetic Cancer Risk Assessment for Black Individuals With Darya Kizub, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Darya Kizub, Hematology-Oncology Fellow at MD Anderson Cancer Center, presented her team's research regarding a novel initiative for recruiting Black individuals to be screened for hereditary cancer genetic testing eligibility. Prior to presenting, she sat down with Oncology Data Advisor to share more about the need to provide cancer genetic testing for Black individuals and the ways that she and her team have partnered with the community to enact this change.
Exploring the Primary Overall Survival Results of Axicabtagene Ciloleucel in the ZUMA-7 Trial With Jason Westin, MD
Oncology Data Advisor® · Exploring Primary Overall Survival Results of Axicabtagene Ciloleucel in ZUMA-7: Jason Westin, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Jason Westin, Director of Lymphoma Clinical Research at MD Anderson Cancer Center, presented the primary overall survival analysis of the phase 3 ZUMA-7 trial investigating axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomas. In this interview, he shares more with Oncology Data Advisor regarding the efficacy, safety, and future directions of this promising agent.
Oncology Data Advisor® · Medical Cannabis Educational Training for Oncology Fellows With Deepa Rangacharia, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor® sat down with Dr. Deepa Rangachari, Director of Hematology/Oncology Graduate Medical Education at Beth Israel Deaconess Medical Center, to learn more about her presentation on her team's development of a novel curriculum to train Hematology/Oncology Fellows in the use of medical cannabis for their patients.